← SynDRA
GALUNISERTIB
SynDRA canonical compound SYN0037177 — structure-anchored drug synonym record
| Clinical phase | Phase 2/Phase 3 |
|---|
| Primary target(s) | TGFBR1 |
|---|
| Mechanism of action | TGF beta receptor inhibitor |
|---|
All known targets
- TGFBR1
- ACVR1B
- BMPR1B
- TGFB1
- TGFBR2
Mechanisms of action (all sources)
- TGFBR1 INHIBITOR
- TGF-beta receptor type I inhibitor
- ACVR1B INHIBITOR
- BMPR1B INHIBITOR
- TGFBR2 INHIBITOR
- TGF beta receptor inhibitor
- TGFBR1 MODULATOR
- TGFB1 INHIBITOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- MAP4K4
- MINK1
- RIPK2
- RIPK3
- CSNK1A1
- TGFB2
- TNIK
- CSNK1D
- CSNK1E
- KDR
- MAPK14
- GAK
- PDXK
- PEBP1
- PDGFRB
- PGRMC1
- PHKG2
- PASK
- PAK6
- PAK4
- PAK2
- PAICS
- PIM1
- PFKP
- PIP4K2C
- PIM2
- PIP4K2A
- OLA1
- PKMYT1
- PKN1
- PKN2
- PLK1
- PLK4
- PRKAA1
- PRKACA
- PRKACB
- PRKACG
- PRKAG1
- PRKAG2
- PRKAR2A
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
Cross-references
Synonyms
- LY-2157299
- LY2157299
- UNII-3OKH1W5LZE
- 4-(2-(6-methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide
- 3OKH1W5LZE
- Galunisertib (LY2157299)
- AK-79916
- 4-[5,6-Dihydro-2-(6-methyl-2-pyridinyl)-4H-pyrrolo[1,2-b]pyrazol-3-yl]-6-quinolinecarboxamide
- 4-(2-(6-Methylpyridin-2-yl)-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazol-3-yl)quinoline-6-carboxamide
- 4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide
- galunisertibum
- CHEBI:137064
- RefChem:142227
- DTXCID00142853
- ly2157299(galunisertib)
- MFCD12923319
- Galunisertib [USAN]
- Galunisertib [USAN:INN]
- Galunisertib (USAN/INN)
- GALUNISERTIB [INN]
- GALUNISERTIB [WHO-DD]
- GTPL7797
- LY2157299(Galunisertib)?
- orb1305376
- SCHEMBL12922153
- SCHEMBL29362145
- EX-A009
- GLXC-90145
- HMS3655D14
- BDBM50015640
- NSC761216
- NSC800103
- s2230
- AKOS022175280
- CCG-264950
- CS-0474
- EX-8675
- FM43366
- NSC-761216
Look up GALUNISERTIB in the interactive SynDRA portal →